share_log

BioCardia Announced A Long-term Partnership To Advance StemCardia's Investigational Pluripotent Stem Cell Product Candidate For The Treatment Of Heart Failure

Moomoo 24/7 ·  Mar 13 07:14

Under the partnership, BioCardia is the exclusive biotherapeutic delivery partner for StemCardia's cell therapy candidate through studies expected to result in FDA approval of an investigational new drug application (IND) and the anticipated Phase I/II clinical development to follow.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment